The Biopharmaceuticals Contract Manufacturing Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size of biopharmaceuticals contract manufacturing has seen swift growth in the past years. The market size is expected to rise from $20.13 billion in 2024 to $22.21 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%.
The biopharmaceuticals contract manufacturing market is projected to reach a size of $33.75 billion in 2029, with a compound annual growth rate (CAGR) of 11.0%.
Download Your Free Sample of the 2025 Biopharmaceuticals Contract Manufacturing Market Report and Uncover Key Trends Now!The key drivers in the biopharmaceuticals contract manufacturing market are:
• Increasing outsourcing trends in the biopharmaceutical sector
• The development and market growth of biosimilars
• The need for a shorter time-to-market in biopharmaceuticals
• An increased focus on specialized services within the sector
The biopharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Product: Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, And Molecular Therapy, Biosimilars
2) By Source: Mammalian, Non-mammalian
3) By Service: Process Development, Fill And Finish Operations, Analytical And QC studies, Packaging
4) By Application: Clinical, Commercial
The key trends in the biopharmaceuticals contract manufacturing market are:
• Technological integration is emerging as a key trend in the biopharmaceuticals contract manufacturing market.
• Outsourcing expansion beyond large molecules is becoming increasingly popular.
• Adoption of advanced manufacturing technologies is shaping the future of the market.
• There is a clear focus on quality and compliance, increasing biosimilars manufacturing.
The major players in the biopharmaceuticals contract manufacturing market are:
• Boehringer Ingelheim GmbH
• Lonza Group Ltd
North America was the largest region in the biopharmaceutical contract manufacturing market in 2024